7 unknown. 7 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 7 | Unknown 7 |
Follow Weight Gain: new trials by email Literature Review of Weight Gain trials Research Report on Weight Gain
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluating the Effects of Adjunctive Aripiprazole on Weight and Metabolic Outcomes in Females Adjunctive Aripiprazole for improving Weight and Metabolic Outcomes in Females - Psychosis, Metabolic Syndrome | Phase 4 | Unknown | Universiti Putra Malaysia | 600 | 2024-09-15 | 2024-09-19 |
| Semaglutide 2.4mg for Low Responders After Bariatric Surgery Placebo, Semaglutide 2.4 MG/0.75 ML Subcutaneous Solution [WEGOVY] - Obesity, Obesity, Morbid | Phase 4 | Unknown | Zuyderland Medisch Centrum | 152 | 2024-05-01 | 2024-03-01 |
| The Effect Tenofovir Disoproxil Fumarate (TDF) and Tenofovir Alafenamide (TAF) on Small Intestine Gut Wall gastroscopy - HIV Infections, Weight Gain | Phase 4 | Unknown | Jussi Sutinen | 24 | 2023-01-19 | 2023-03-27 |
| Changes in Weight, Body Composition and Metabolic Parameters After Discontinuing Dolutegravir or Tenofovir Disproxil Dolutegravir/Lamivudine 50 MG-300 MG Oral Tablet [DOVATO], Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate 100 MG-300 MG-300 MG Oral Tablet [DELSTRIGO] - Hiv, HIV Infections | Phase 4 | Unknown | Thomas Benfield | 126 | 2021-02-02 | 2021-05-27 |
| Lorcaserin for Weight Loss Management in Patients on Antipsychotics: A Pilot Study lorcaserin, Intensive dietary counseling - Weight Gain | Phase 4 | Unknown | Southern California Institute for Research and Education | 15 | 2014-01-01 | 2014-01-30 |
| Reversal of Antipsychotic-Induced Hyperprolactinemia, Weight Gain, Hyperglycemia and Dyslipidemia Abilify (aripiprazole) - Hyperprolactinemia, Weight Gain | Phase 4 | Unknown | Genovate Biotechnology Co., Ltd., | 2007-10-01 | 2007-10-10 | |
| Diabetes Prevention Program in Schizophrenia [DPPS] Modified diabetes prevention protocol & Metformin - Diabetes Mellitus, Schizophrenia | Phase 4 | Unknown | Hamilton Health Sciences Corporation | 200 | 2005-02-01 | 2005-09-16 |
HIV Infections (2) · Obesity (2) · Acquired Immunodeficiency Syndrome (1) · Diabetes Mellitus (1) · Dyslipidemias (1) · Hyperprolactinemia (1) · Metabolic Syndrome (1) · Obesity, Morbid (1) · Osteoporosis (1) · Psychotic Disorders (1) · Renal Insufficiency (1) · Schizophrenia (1) · Weight Loss (1)
Body Weight (7) · Body Weight Changes (7) · Pathological Conditions, Signs and Symptoms (7) · Signs and Symptoms (7) · Nutritional and Metabolic Diseases (5) · Metabolic Diseases (4) · Blood-Borne Infections (2) · Communicable Diseases (2) · Endocrine System Diseases (2) · Genital Diseases (2) · Glucose Metabolism Disorders (2) · Immune System Diseases (2) · Immunologic Deficiency Syndromes (2) · Infections (2) · Lentivirus Infections (2)
Aripiprazole (1) · Gastroscopy (1) · Lamivudine (1) · Metformin (1) · Tenofovir (1) · dolutegravir (1) · doravirine (1) · lorcaserin (1) · semaglutide (1)
Genovate Biotechnology Co., Ltd., (1) · Hamilton Health Sciences Corporation (1) · Jussi Sutinen (1) · Southern California Institute for Research and Education (1) · Thomas Benfield (1) · Universiti Putra Malaysia (1) · Zuyderland Medisch Centrum (1)
Canada (1) · Denmark (1) · Finland (1) · United States (1)
Chen Chih-Ken, PhD (1) · Jan Willem Greve, prof (1) · Jussi Sutinen (1) · Lakshmi P Voruganti, MD (1) · Thomas Benfield, MD (1)
PMID 17539698, PMID 20732372, PMID 22398127, PMID 27147592, PMID 33800403, PMID 39039812